HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice.
Rattachement africain : fr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
e13020 Background: Until 2020, in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), the two first lines of metastatic treatment were well defined but after, many options were possible, most often combining targeted therapy plus chemotherapy. Eribulin mesylate is indicated for the treatment of patients with ABC previously treated by anthracycline and taxane regimens in the advanced setting. Here, we present the results of eribuline and trastuzumab (E/T) combination in HER2-positive ABC previously treated. Methods: Patients with HER2-positive ABC treated with the E/T combination from our region cancer institute were included in this retrospective study. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR) and safety. Results: Between November 2013 and July 2019, a total of 34 consecutive patients with HER2-positive ABC were included. The median number of previous lines for advanced setting was 4 (range 2-7). Patients treated by taxanes and anthracyclines represented 91% and 47% respectively; 50%, 79% and 62% were previously treated with pertuzumab, trastuzumab emtansine and lapatinib respectively. After a median follow up of 24.8 months, median PFS was 6.2 months (95% CI [3.35-7.13]) and median OS was 12.6 months (95% CI [7.13-18.56]). The ORR and CBR were 38% and 53%, respectively. No unexpected adverse event was observed. The most frequent grade 3-4 toxicity was hematologic (44.1%). Conclusions: Recently, new therapies have revolutionized the management of HER2-positive ABC and patients benefit from a prolonged overall survival associated with a maintained performance status. However, in pretreated and advanced metastatic setting, there are few scientific evidence to guide the choice of treatments. A combination of E/T could be an effective option in patients with good performance status and willing to receive treatment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice.
- Date Crossref
- 01/06/2022
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Inserm pays non établi dans la noticeOrganisme public
-
Methodology and Quality of Life Unit in Oncology pays non établi dans la noticeStructure de recherche
-
Centre Hospitalier Universitaire de Besançon pays non établi dans la noticeÉtablissement de santé
-
Université de Franche-Comté pays non établi dans la noticeUniversité ou école supérieure
-
Department of Medical Oncology pays non établi dans la noticeInstitution
-
University Hospital Methodological and Quality of Life Unit in Oncology (INSERM UMR 1098) pays non établi dans la noticeUniversité ou école supérieure
-
Department of Medical Onclogy pays non établi dans la noticeInstitution
-
CHU Jean Minjoz Service d'Oncologie Médicale pays non établi dans la noticeÉtablissement de santé
-
CHU Minjoz Medical Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
Institut Regional du Cancer en Franche-Comté pays non établi dans la noticeStructure de recherche
-
CHU Besançon Department of Oncology pays non établi dans la noticeÉtablissement de santé
Inserm, Methodology and Quality of Life Unit in Oncology et Centre Hospitalier Universitaire de Besançon, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.